BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35544458)

  • 21. Role of arsenic trioxide in acute promyelocytic leukemia.
    Iland HJ; Seymour JF
    Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapies for newly diagnosed acute promyelocytic leukemia].
    Yokoyama Y
    Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Testa U; Lo-Coco F
    Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute promyelocytic leukemia in childhood.
    Gregory J; Feusner J
    Curr Oncol Rep; 2009 Nov; 11(6):439-45. PubMed ID: 19840521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
    Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
    Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case report: Identification of a novel HNRNPC::RARG fusion in acute promyelocytic leukemia lacking RARA rearrangement.
    Ding W; Weng G; Wang Z; Guo Y; Wang M; Shen H; Chen S; Du X; Wen L
    Front Oncol; 2022; 12():1028651. PubMed ID: 36713535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the role of arsenic in newly diagnosed APL?
    Tallman MS
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
    Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
    Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
    Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
    Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current treatment strategy of acute promyelocytic leukemia.
    Mi J
    Front Med; 2011 Dec; 5(4):341-7. PubMed ID: 22198746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [State-of-the-art treatment of acute promyelocytic leukemia].
    Kiguchi T
    Rinsho Ketsueki; 2018; 59(10):2007-2018. PubMed ID: 30305503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
    Breccia M; Foà R
    Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
    Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
    Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How to manage acute promyelocytic leukemia.
    Mi JQ; Li JM; Shen ZX; Chen SJ; Chen Z
    Leukemia; 2012 Aug; 26(8):1743-51. PubMed ID: 22422168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
    Guo W; Wang H; Zhao W
    Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
    Zhu G
    Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute promyelocytic leukemia current treatment algorithms.
    Yilmaz M; Kantarjian H; Ravandi F
    Blood Cancer J; 2021 Jun; 11(6):123. PubMed ID: 34193815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
    Hu J; Liu YF; Wu CF; Xu F; Shen ZX; Zhu YM; Li JM; Tang W; Zhao WL; Wu W; Sun HP; Chen QS; Chen B; Zhou GB; Zelent A; Waxman S; Wang ZY; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3342-7. PubMed ID: 19225113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.